Viewing data from:

ZIPRASIDONE MESYLATE

ANDA

ZIPRASIDONE MESYLATE | A211908 | GLAND PHARMA LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: GEODON(TE code: AP)

Medicare Part D Spending

CMS annual spending data for Ziprasidone Mesylate (2023)

Total Spending

$503K

Total Claims

2,850

Beneficiaries

1,296

Avg Cost/Unit

$34.77

Spending Trend

$163K(2020)→$409K(2021)→$449K(2022)→$503K(2023)

YoY Change:-1.4%

5yr CAGR:-3.5%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain3 active DMFs

3 active API suppliers hold Drug Master Files for this ingredient.

MSN LIFE SCIENCES PRIVATE LTDZIPRASIDONE MESYLATE TRIHYDRATE

DMF 347152020

SUN PHARMACEUTICAL INDUSTRIES LTDZIPRASIDONE MESYLATE TRIHYDRATE

DMF 377592023

APITORIA PHARMA PRIVATE LTDZIPRASIDONE MESYLATE TRIHYDRATE

DMF 387452023

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Mar 17, 2020	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 20MG BASE/VIAL

0 patents0 exclusivities▴

POWDER;INTRAMUSCULAR | Approved: Dec 26, 2019

No patent or exclusivity listings for this strength.